AU2001229672A1 - Use of ribose supplementation for increasing muscle mass and decreasing body fatin humans - Google Patents

Use of ribose supplementation for increasing muscle mass and decreasing body fatin humans

Info

Publication number
AU2001229672A1
AU2001229672A1 AU2001229672A AU2967201A AU2001229672A1 AU 2001229672 A1 AU2001229672 A1 AU 2001229672A1 AU 2001229672 A AU2001229672 A AU 2001229672A AU 2967201 A AU2967201 A AU 2967201A AU 2001229672 A1 AU2001229672 A1 AU 2001229672A1
Authority
AU
Australia
Prior art keywords
fatin
humans
muscle mass
increasing muscle
decreasing body
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001229672A
Inventor
Terri Butler
Scott Hagerman
Lou Vazquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioenergy Inc
Original Assignee
Bioenergy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioenergy Inc filed Critical Bioenergy Inc
Publication of AU2001229672A1 publication Critical patent/AU2001229672A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
AU2001229672A 2000-01-20 2001-01-19 Use of ribose supplementation for increasing muscle mass and decreasing body fatin humans Abandoned AU2001229672A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17713900P 2000-01-20 2000-01-20
US60177139 2000-01-20
PCT/US2001/001964 WO2001052831A1 (en) 2000-01-20 2001-01-19 Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans

Publications (1)

Publication Number Publication Date
AU2001229672A1 true AU2001229672A1 (en) 2001-07-31

Family

ID=22647350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001229672A Abandoned AU2001229672A1 (en) 2000-01-20 2001-01-19 Use of ribose supplementation for increasing muscle mass and decreasing body fatin humans

Country Status (3)

Country Link
US (1) US6525027B2 (en)
AU (1) AU2001229672A1 (en)
WO (1) WO2001052831A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050048136A1 (en) * 2003-08-27 2005-03-03 Choudhry Muhammad S. Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness
AU2005204946B2 (en) * 2004-01-14 2010-03-11 Bioenergy, Inc. Use of ribose in recovery from anaesthesia
WO2005089774A1 (en) * 2004-03-18 2005-09-29 Tanabe Seiyaku Co., Ltd. D-ribose for improving depression-like symptoms
US20100099630A1 (en) * 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
ES2393786T3 (en) * 2004-04-29 2012-12-28 Ribocor, Inc. Method to improve ventilatory efficiency
US7566463B2 (en) * 2006-05-03 2009-07-28 C. B. Fleet Company Oral rehydration compositions
JP5396387B2 (en) * 2007-01-23 2014-01-22 バイオエナジー インコーポレイティド Use of D-ribose to treat cardiac arrhythmias
US20090061016A1 (en) * 2007-09-05 2009-03-05 Selzer Jonathan A Seawater Based Dietary Supplement Product for Energy and Electrolyte Replacement
US7790688B2 (en) * 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US20100055206A1 (en) * 2008-04-02 2010-03-04 St Cyr John A Use of ribose in first response to acute myocardial infarction
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
WO2017075289A1 (en) 2015-10-27 2017-05-04 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
WO2017120731A1 (en) * 2016-01-11 2017-07-20 Shanghai Yao Yuan Biotechnology Co., Ltd. Methods and compositions for reducing body weight
EP4241838A3 (en) 2016-02-01 2023-12-20 Bioenergy Life Science, Inc. Use of ribose for treatment of subjects having congestive heart failure
US11865121B2 (en) * 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE427983B (en) * 1980-02-15 1983-05-30 Pripps Bryggerier Ab BEVERAGE PRODUCTS
US5114723A (en) * 1990-02-27 1992-05-19 University Of Texas System Board Of Regents Beverage compositions for human consumption
US5294606A (en) * 1992-11-24 1994-03-15 Reliv' International Inc. Isotonic energy composition and method to use same
US5397786A (en) * 1993-01-08 1995-03-14 Simone; Charles B. Rehydration drink
US6192942B1 (en) 1996-01-29 2001-02-27 Hybritech Polymers Multi-layer tubing assembly for fluid and vapor handling systems
GB9715340D0 (en) * 1997-07-22 1997-09-24 Cerestar Holding Bv Beverages for enhanced physical performance
US6192043B1 (en) 1998-05-01 2001-02-20 3Com Corporation Method of caching routes in asynchronous transfer mode PNNI networks
US6218366B1 (en) 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US6429198B1 (en) * 1999-04-12 2002-08-06 Bioenergy Inc. Compositions for increasing athletic performance in mammals
US6159943A (en) 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles

Also Published As

Publication number Publication date
WO2001052831A1 (en) 2001-07-26
US20020035069A1 (en) 2002-03-21
US6525027B2 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
AU2001229672A1 (en) Use of ribose supplementation for increasing muscle mass and decreasing body fatin humans
EP1283707A4 (en) Polymerizable compositions and methods of use
AU2002363797A1 (en) Compression garment for selective application of treatment of lymphedema and related illnesses manifested at various location of the body
AU4976001A (en) Mucin-1 specific binding members and methods of use thereof
PL366038A1 (en) Nucleoside compounds and uses thereof
IL157667A0 (en) Improved skin substitutes and uses thereof
AU2002314466A1 (en) Withasol and methods of use
AU2001281850A1 (en) Use of inulin and inulin derivatives
AU2001255199A1 (en) Ceramide derivatives and method of use
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2002359512A1 (en) Belts and methods of use thereof
AU6608201A (en) Dietary lipids for improving skin and coat of pets
IL211958A0 (en) Lactone formulations and method of use
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
IL157975A0 (en) Synthetic derivatives of 21-butenyl and related spinosyns
AU2002239933A1 (en) Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2001268236A1 (en) Use of aicar and related compounds
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2001297556A1 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
GB0003201D0 (en) Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
IL162014A0 (en) Shape-recovering material suitable for application of an attachment, and its use
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
EP1392460A4 (en) Hydrogenfluorides of aminosilanols and their use